Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading ...
persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...
– Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the ...
Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...
By Kamal Choudhury and Sriparna Roy March 5 (Reuters) - Roche said on Thursday its experimental obesity drug, which it is ...
Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for ...
– The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D – – The facility will create more than 1,900 jobs and support the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
Swiss pharma giant Roche’s RHHBY Genentech announced a significant expansion of its original investment in a new manufacturing facility in Holly Springs, NC. Genentech will more than double the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results